Animal Model Market Overview
The Animal Model Market is witnessing strong growth as pharmaceutical and biotechnology companies increase investment in preclinical research, drug discovery, and advanced disease modeling. Advancements in genetic engineering, CRISPR-based technologies, and personalized medicine are improving the precision and predictive value of animal models, supporting more effective therapeutic development.
The global Animal Model Market was valued at USD 2.78 billion in 2024 and is projected to grow from USD 2.98 billion in 2025 to USD 5.92 billion by 2035, registering a 7.12% CAGR during 2025–2035. North America led the market with more than 50.04% revenue share in 2024, while pharmaceutical companies accounted for 62% of market revenue. Mice represented 60% of the market, oncology accounted for 55%, and drug discovery held a 52% share.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/sample_request/9709
Key Players
Charles River Laboratories, Envigo, Taconic Biosciences, Harlan Laboratories, Crown Bioscience, Janvier Labs, The Jackson Laboratory, WuXi AppTec, and Inotiv are among the major participants in the global Animal Model Market.
Market Drivers and Trends
Growing investment in biopharmaceutical research and drug discovery is increasing demand for advanced animal models that can support preclinical efficacy and safety testing. The expansion of pharmaceutical R&D pipelines is strengthening the role of animal models in therapeutic development.
Advancements in genetic engineering, including CRISPR and other gene-editing technologies, are enabling researchers to create more precise models that better replicate human diseases. These developments are improving disease modeling and the predictability of therapeutic responses.
The growing demand for biopharmaceuticals is another major growth driver, as companies require reliable preclinical models to evaluate innovative therapies before clinical development. Increasing R&D expenditure across pharmaceutical and biotechnology organizations is further supporting market expansion.
Market Segmentation
By Application, the market is segmented into Drug Discovery, Toxicology Testing, Genetic Research, Disease Modeling, and Regenerative Medicine. Drug Discovery is the largest application, accounting for 52% of the market, while Toxicology Testing is experiencing strong growth due to increasing regulatory requirements.
By Type of Animal Model, the market includes Mice, Rats, Non-Human Primates, Zebrafish, and Guinea Pigs. Mice dominate with a 60% share because of their genetic similarity to humans, cost efficiency, and versatility, while Non-Human Primates represent a rapidly growing category for complex disease and drug-development research.
By Research Area, the market covers Oncology, Neurology, Cardiology, Immunology, and Metabolic Disorders. Oncology leads with a 55% share, while neurology is emerging rapidly as research into neurodegenerative and neurological diseases expands.
By End User, the market is segmented into Pharmaceutical Companies, Biotechnology Firms, Academic Institutions, Contract Research Organizations, and Government Research Laboratories. Pharmaceutical companies hold the largest share at 62%, while biotechnology firms are identified as the fastest-growing end-user segment.
Market Opportunities
Advances in genetic engineering are creating opportunities for the development of highly precise genetically modified animal models for drug discovery and precision medicine. These models can improve disease replication and help researchers evaluate therapeutic responses more effectively.
The expansion of contract research organizations is another opportunity, as pharmaceutical and biotechnology companies increasingly rely on specialized preclinical research capabilities. Emerging markets, particularly across Asia-Pacific and Latin America, also offer opportunities as biomedical infrastructure and research investment expand.
Recent Developments and Market Trends:
Technological innovation is reshaping animal-model development, with CRISPR gene editing and advanced imaging techniques enabling more precise genetic modifications and improving the accuracy of disease models.
Ethical research practices and regulatory compliance are becoming increasingly important. Greater alignment with humane research standards is encouraging refinement of existing practices and greater transparency in animal-based research.
Collaboration between academic institutions and pharmaceutical companies is expanding, supporting the creation of specialized animal models and accelerating drug discovery and translational research.
Emerging markets are contributing increasingly to industry growth as investments in biomedical research and healthcare infrastructure expand. The globalization of research is encouraging the establishment of regional animal-model facilities and stronger scientific partnerships.
Demand for advanced models is also being reinforced by the growth of personalized medicine and complex therapeutic development, encouraging greater use of genetically engineered models across oncology, immunology, rare diseases, and other research areas.
Reasons to Buy the Report:
Understand the projected growth of the Animal Model Market through 2035, including market size and the 7.12% CAGR forecast.
Assess the competitive landscape and identify major companies involved in animal-model development and preclinical research.
Analyze major applications, including drug discovery, toxicology testing, genetic research, disease modeling, and regenerative medicine.
Evaluate demand across animal-model types, research areas, and end-user categories.
Identify emerging opportunities associated with genetic engineering, personalized medicine, biotechnology investment, CRO expansion, and emerging research markets.
Future Outlook
The Animal Model Market is projected to reach USD 5.92 billion by 2035, expanding at a 7.12% CAGR from 2025 to 2035. Continued investment in biopharmaceutical research, advancements in biotechnology, regulatory support, and the growing need for accurate preclinical models are expected to sustain market growth.
Future opportunities are expected to center on genetically modified models for precision medicine, expanded services from contract research organizations, and the integration of advanced technologies for research and data analysis. Strategic collaborations between pharmaceutical companies, biotechnology firms, academic institutions, and specialized research providers are likely to further strengthen the market ecosystem.
➤➤Explore Our Latest Related Reports:
